The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies like Giredestrant, Camizestrant, and VEPPANU, the first FDA-approved PROTAC therapy, are reshaping treatment options and expanding market opportunities. The US leads the market, with about 40% of advanced breast cancer patients developing ESR1 mutations during first-line therapy, which reduces treatment effectiveness. Emerging drugs are expected to transform the treatment landscape and improve patient outcomes in the coming decade.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
